Compare Logitech International SA (LOGI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Logitech International SA trades at $101.24 (market cap $14.62B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Logitech International SA is far larger — about 15× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Logitech International SA pays a 1.64% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LOGI | MRVI | |
|---|---|---|
Market Cap | $14.62B | $977.37M |
Volume | 345,412 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $126.69 | $9.00 |
52-Week Low | $85.84 | $2.83 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $1.08B |
Dividend Yield | 1.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $102.77, up 4.52% on the day, reflecting strong momentum. The stock exhibits a bullish technical trend, supported by moving averages, and trades near its pivot point of $102. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.85 surpassing the $1.26 expectation. The company maintains robust profitability, with a net income margin of 16.28% and ROE of 35.29%. Positive developments include new product launches like the Zone Vibe Pro headset and a partnership with SEGA for Crazy Taxi: World Tour.
The outlook for LOGI is cautiously optimistic, driven by earnings beats and strategic initiatives, though analyst consensus is mixed with a $107 price target. Key opportunities include product innovation and hybrid work trends, while risks involve chip shortage challenges and competitive pressures. The stock's valuation, with a P/E of 18.55, appears reasonable given growth prospects, but investors should monitor execution against guidance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
